Searched for
GLENMARK NEWS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Capitalmind Flexi Cap Fund exits RIL and 2 others, hikes stake in Titan Company, MCX and 16 other stocks in AprilCapitalmind Flexi Cap Fund exited Reliance Industries, Bank of Baroda, and L&T Finance in April. The fund also increased stakes in Titan Co...
- Nifty finds support: Nagaraj Shetti spots 2 breakout stocks worth watchingNifty's Monday pullback is a technical dip, not a trend reversal, says HDFC Securities analyst Nagaraj Shetti. After forming a higher botto...
- US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Glenmark settles drug pricing case with US Department of JusticeUS-based Glenmark Pharmaceuticals Inc, a subsidiary of the company, has entered into a three-year deferred prosecution agreement with DOJ i...
- Glenmark drops 6% as Q2 net profit declinesThe stock has nearly trebled from its March lows of Rs 168, and is up 39 per cent year-to-date.
- Glenmark's Ankleshwar plant gets EIR report from USFDA"The EIR is issued by the FDA only if it finds the facility to be deemed acceptable," the company said in a BSE filing.
- Prefer Glenmark on strong molecule pipeline; Sun Pharma a value arbitrage opportunity: Prakash DiwanThere are certain smaller names as well, which would start bouncing back, believes Diwan. The analyst pointed out that Suven Life has falle...
- Need to be cautious on Glenmark amid negative news flow: Miintdirect.com"It is clearly a bad news for Glenmark until we do not know what would be the material impact," Gorakssakar said.
- Glenmark Pharmaceuticals gains 7% on Q2 results; brokerages maintain buyThe company had posted a net profit of Rs 56.58 crore for the quarter ended September 30, 2011, Glenmark Pharmaceuticals said in a statemen...
- Glenmark files arbitration claim against Napo PharmaceuticalsGlenmark has filed arbitration claims against Napo Pharmaceuticals for ending a contract to develop and market diarrhea drug.
- Buy Glenmark Pharma: CK Narayan, Sharyans ResourcesYou had this huge move up, 16-17% in the morning and now trailing off a bit on some amount of profit taking no doubt, but the fact that thi...
- 290-300 a decent level to get into Glenmark.: Ashwani Gujral, Market StrategistGenerally if you buy Glenmark when there is a bad news, it tends to have periods of good news as well.
- Glenmark Pharma may see more downside: Deepak MohoniThe market conditions, in the last week or two, have been quite adverse and that usually has an impact on Glenmark.
- Buy Glenmark Pharma: Ashwani Gujral"Glenmark is something that you can buy because the pharma space continues to look okay."
- Glenmark looks good medium term : Sharyans ResourcesGlenmark is something which could be looked at from a positive aspect across several weeks and months, both at the current level as well as...
- Glenmark Pharma: Miles to go before new drug makes a markGlenmark’s partners — US-based Napo Pharmaceuticals and Salix Pharmaceuticals — have announced completion of phase-III trials for the drug ...
- Stay out of Glenmark as a long term investor: Deepak MohoniDeepak Mohoni, Director, trendwatchindia.com in a chat with ET Now gives his perspective on Glenmark.
- Optimistic about Glenmark: Gaurang Shah, Geojit BNP Paribas Financial ServicesGaurang Shah, Asst VP, Geojit BNP Paribas Financial Services, in a chat with ET Now talks about Glenmark.
Load More
